Do you have patients who may be appropriate for KEYTRUDA®? Explore the materials below to get to know the efficacy and safety profile across indications and learn about profiles of patients* who may be eligible for KEYTRUDA®.
-
Download an overview of the pivotal trial KEYNOTE-177, including patient demographics, efficacy results, and the safety profile.
Download now Access the journal publication -
ESO Nutshell Letter
A resource to help you review the latest KEYTRUDA® clinical data in esophageal cancer
Download Now -
HNSCC patient profiles
See HNSCC patient* profiles and find out if they reflect patients in your practice.
Unresectable recurrent HNSCC (treatment-experienced patients)
Do you see patients like André*?
Download nowDoes Marianne* reflect the patients in your practice?
Download nowMetastatic HNSCC (treatment-naïve patients)
Is Robert* consistent with patients that you see?
Download nowDoes your practice include patients like William*?
Download now -
Melanoma Dosing Card
A tool to provide you with a quick reference on the KEYTRUDA® melanoma dosing regimen
Download nowMelanoma Patient profiles
See patient* profiles, view relevant data, and see if KEYTRUDA® could be an option for your patients with melanoma.
Pranav
Unresectable stage IV melanoma with extensive metastasis
Treatment-naïve to ipilimumab
*Fictitious patient profile. May not be representative of all patients.
Lim*
Stage III
melanoma with lymph nodes involvementTreatment-naïve to ipilimumab
*Fictitious patient profile. May not be representative of all patients.
Kristina*
Completely resected stage IIC melanoma
Candidate for adjuvant treatment
*Fictitious patient profile. May not be representative of all patients.
Jun*
Unresectable stage IV melanoma
Previously treated with ipilimumab
*Fictitious patient profile. May not be representative of all patients.
James*
Completely resected stage IIB melanoma
Candidate for adjuvant treatment
*Fictitious patient profile. May not be representative of all patients.
-
Kidney Cancer Research Network of Canada 2021 consensus statement
Read it here -
TNBC Nutshell Letter
A resource to help you review the latest KEYTRUDA® clinical data in TNBC
Download now -
Learn about KEYTRUDA® in urothelial carcinoma by downloading our clinical overviews.
Explore the overall survival data from pivotal trial KEYNOTE-045
Download nowLearn about the efficacy and safety results from trial KEYNOTE-045
Download now